FDA peptide advisory panel to include doctors and pharmacists with financial ties to unproven peptide industry

Jun 29, 2026

The U.S. FDA has appointed eight new members to its drug compounding advisory committee, shifting its makeup from academic researchers to industry-linked clinicians and pharmacists. Set to meet in July 2026 to review controversial peptides like BPC-157, the panel now includes proponents who actively sell or promote these unproven chemicals. This restructuring aligns with Health Secretary Robert F. Kennedy Jr.'s efforts to reshape health policy, raising significant conflict-of-interest concerns.

FDA peptide advisory panel

▪The newly formulated FDA advisory committee will meet in July 2026 to reconsider the safety and effectiveness of seven popular peptide injections.
▪Previous versions of the FDA compounding panel were composed of academic researchers from universities including Duke, Harvard, and Johns Hopkins.
▪The U.S. Food and Drug Administration published the names of eight new members appointed to an advisory committee on drug compounding.

Panel members' financial conflicts

▪New FDA panelist Bobby Harshbarger is a Tennessee state senator and a pharmacist at Premiere Pharmacy, which sells compounded medications.
▪New FDA panelist Dr. Haleem Mohammed runs Gameday Men's Health clinics in Florida that sell peptide injections and state online that their compounded medications are not FDA-approved.
▪The majority of the newly appointed FDA advisory committee members are health professionals who prescribe, produce, or promote peptides.
▪New FDA panelist Dr. Gabriel Alizaidy charges $500 for peptide consultations and promotes substances like BPC-157 and GHK-Cu on social media.

RFK Jr. peptide promotion

▪U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly praised peptides and described using them to recover from injuries.
▪The restructuring of the FDA advisory panel aligns with efforts by Robert F. Kennedy Jr. to reshape U.S. health policy under the Make America Healthy Again movement.

Unproven peptide industry ties

▪The FDA has warned for several years about the health risks of injecting unproven chemicals like BPC-157 and TB-500, which are considered doping substances by sports authorities.
▪Peptide sellers frequently circumvent U.S. regulatory frameworks by labeling their products as 'for research use only' because the FDA does not regulate research chemicals.